Lessons from the Atomic Bomb About Secondary MDS

Abstract Myelodysplastic syndromes (MDSs) is a hematological neoplasm defined by ineffective hematopoiesis, dysplasia of hematopoietic cells, and risk of progression to acute leukemia. MDS occurs as de novo or secondary, and chemoradiotherapy for cancers is thought to increase the risk of MDS among patients. Recently, an epidemiological study for MDS among A-bomb survivors was performed, and it clearly demonstrated that the exposure to external radiation significantly increased the risk of MDS. Precise epidemiological data among survivors have revealed important clinical factors related to the risk of leukemias. In this review, by comparing data for secondary MDS and leukemia/MDS among survivors, several factors which would affect the risk of MDS, especially secondary MDS, are discussed.
Source: Current Hematologic Malignancy Reports - Category: Hematology Source Type: research

Related Links:

This study nicely illustrates the importance of the cellular metabolic state of myeloid cells: it highlights that not only the availability of glucose, but also its channeling into different pathways (glycolysis versus glycogen synthesis) contributes to maintaining proper myeloid function. On the Ability of Redundant Blood Vessels to Lower Cardiovascular Mortality https://www.fightaging.org/archives/2021/11/on-the-ability-of-redundant-blood-vessels-to-lower-cardiovascular-mortality/ A few strategies offer the possibility of growing additional redundant blood vessels, though this is far from rigorously pr...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Chromosomal aberrations are found in ≥ 40% of hematologic neoplasms such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) [1]. Chromosomal aberrations closely influence treatment and prognosis of AML and MDS patients. Tumor cells derived from AML show mainly balanced rearrangements that result in fusion genes, wher eas unbalanced chromosomal aberrations that result in loss or gain of genetic material are observed more frequently in tumor cells derived from MDS patients [1]. A normal karyotype (46,XX or 46,XY) is observed in nearly half of the patients.
Source: Cancer Genetics and Cytogenetics - Category: Genetics & Stem Cells Authors: Source Type: research
Cancers, Vol. 13, Pages 5640: The Burden of Survivorship on Hematological Patients—Long-Term Analysis of Toxicities after Total Body Irradiation and Allogeneic Stem Cell Transplantation Cancers doi: 10.3390/cancers13225640 Authors: Michael Oertel Jonas Martel Jan-Henrik Mikesch Sergiu Scobioala Christian Reicherts Kai Kröger Georg Lenz Matthias Stelljes Hans Theodor Eich Total body irradiation is an effective conditioning modality before autologous or allogeneic stem cell transplantation. With the whole body being the radiation target volume, a diverse spectrum of toxicities has been repo...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Fanconi anemia (FA) is a disease of genomic instability and cancer. In addition to DNA damage repair, FA pathway proteins are now known to be critical for maintaining faithful chromosome segregation during mitosis. While impaired DNA damage repair has been studied extensively in FA-associated carcinogenesis in vivo, the oncogenic contribution of mitotic abnormalities secondary to FA pathway deficiency remains incompletely understood. To examine the role of mitotic dysregulation in FA pathway deficient malignancies, we genetically exacerbated the baseline mitotic defect in Fancc-/- mice by introducing heterozygosity of the ...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
rengère Troadec Myelodysplastic syndromes (MDSs) are heterogeneous for their morphology, clinical characteristics, survival of patients, and evolution to acute myeloid leukemia. Different prognostic scoring systems including the International Prognostic Scoring System (IPSS), the Revised IPSS, the WHO Typed Prognostic Scoring System, and the Lower-Risk Prognostic Scoring System have been introduced for categorizing the highly variable clinical outcomes. However, not considered by current MDS prognosis classification systems, gene variants have been identified for their contribution to the clinical heterogeneity ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Acute myeloid leukemia (AML) cells can evade innate immune killing by modulating natural killer (NK) cells receptors and their cognate ligands in tumor cells, thus it may be possible to restore proper expression of immune receptors or ligands with immune sensitive drugs. Decitabine, as a hypomethylation agent, was approved for the treatment of AML and myelodysplastic syndrome. While clinical responses were contributed by epigenetic effects and the induction of cancer cell apoptosis, decitabine also has immune-mediated anti-tumor effects. After exposure to various concentration of decitabine for 24 h, the primary NK ce...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
CONCLUSION: In conclusion, Treo/Flu/AraC provides tolerable, feasible, and effective conditioning for patients with AML, MDS or MPN, even in advanced disease states. The incidence of NRM and relapse is acceptable in this heavily pre-treated population with high-risk disease. Future research will aim to confirm these initial findings and include a larger number of participants in a prospective trial.PMID:34674031 | DOI:10.1007/s00432-021-03836-8
Source: Clin Med Res - Category: Research Authors: Source Type: research
Cogle Tara L. Lin We evaluate the risk, characteristics and biomarkers of treatment-emergent cytokine release syndrome (CRS) in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who received APVO436 during the dose-escalation phase of a Phase 1B study (ClinicalTrials.gov, identifier: NCT03647800). Of four patients who developed Grade ≥ 3 CRS, two received steroid prophylaxis. The dose level, gender, race, obesity, or baseline hematologic parameters in peripheral blood did not predict the risk of CRS. Patients with a higher leukemia burden as determined by a higher tot...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
CONCLUSIONS: The MPS has provided provocative insights into the possible range of health effects following low-level chronic radiation exposure. When the 34 MPS cohorts are completed and combined, a powerful evaluation of radiation-effects will be possible. This final article in the MPS special issue summarizes the findings to date and the possibilities for the future. A National Center for Radiation Epidemiology and Biology is envisioned.PMID:34669549 | DOI:10.1080/09553002.2021.1988183
Source: International Journal of Radiation Biology - Category: Radiology Authors: Source Type: research
Fang Lenalidomide as well as other immunomodulatory drugs (IMiDs) have achieved clinical efficacies in certain sub-types of hematologic malignancies, such as multiple myeloma, lower-risk myelodysplastic syndromes (MDS) with a single deletion of chromosome 5q (del(5q)) and others. Despite superior clinical response to lenalidomide in hematologic malignancies, relapse and resistance remains a problem in IMiD-based therapy. The last ten years have witnessed the discovery of novel molecular mechanism of IMiD-based anti-tumor therapy. IMiDs bind human cereblon (CRBN), the substrate receptor of the CRL4 E3 ubiquitin ligase ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
More News: Acute Leukemia | Cancer | Cancer & Oncology | Epidemiology | Hematology | Lessons | Leukemia | Myelodysplastic Syndrome | Study